Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Mallinckrodt
Johnson and Johnson
Harvard Business School
AstraZeneca

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INTERFERON ALFA-N3

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for interferon alfa-n3

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000401 Oral Collagen for Rheumatoid Arthritis Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 2 1999-07-01 Rheumatoid arthritis (RA) is an autoimmune disease characterized by swelling and inflammation of the joints. In RA, the immune system attacks a person's own cells inside joints, eventually leading to joint damage and disability. This study will determine if oral bovine type II collagen (bovine CII) will lead to decreased joint inflammation in RA patients.
NCT00000401 Oral Collagen for Rheumatoid Arthritis Completed University of Tennessee Phase 2 1999-07-01 Rheumatoid arthritis (RA) is an autoimmune disease characterized by swelling and inflammation of the joints. In RA, the immune system attacks a person's own cells inside joints, eventually leading to joint damage and disability. This study will determine if oral bovine type II collagen (bovine CII) will lead to decreased joint inflammation in RA patients.
NCT00000647 An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 To restore immunologic function and virus-free state in HIV-infected patients. Based on previous studies showing temporary improvement in immune function in HIV-infected patients using peripheral lymphocyte transfers and bone marrow transplantation, and based on studies documenting the antiretroviral effects of zidovudine (AZT) and interferon-alfa (IFN-A) as well as the preliminary test tube and patient studies suggesting anti-HIV effects of recombinant CD4-IgG, we propose to treat HIV-infected patients using combination antiretroviral therapy with transplantation of bone marrow and peripheral lymphocytes from previously immunized donors in an attempt to restore immunologic function and a virus-free state.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for interferon alfa-n3

Condition Name

Condition Name for interferon alfa-n3
Intervention Trials
Hepatitis C 215
Hepatitis C, Chronic 136
Chronic Hepatitis C 124
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for interferon alfa-n3
Intervention Trials
Hepatitis 646
Hepatitis C 587
Hepatitis A 524
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for interferon alfa-n3

Trials by Country

Trials by Country for interferon alfa-n3
Location Trials
Canada 349
Germany 302
Brazil 96
Poland 90
Belgium 86
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for interferon alfa-n3
Location Trials
Texas 248
California 238
New York 223
Maryland 201
Florida 165
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for interferon alfa-n3

Clinical Trial Phase

Clinical Trial Phase for interferon alfa-n3
Clinical Trial Phase Trials
Phase 4 251
Phase 3 344
Phase 2/Phase 3 48
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for interferon alfa-n3
Clinical Trial Phase Trials
Completed 896
Recruiting 205
Terminated 142
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for interferon alfa-n3

Sponsor Name

Sponsor Name for interferon alfa-n3
Sponsor Trials
National Cancer Institute (NCI) 139
Hoffmann-La Roche 95
Merck Sharp & Dohme Corp. 83
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for interferon alfa-n3
Sponsor Trials
Other 1443
Industry 902
NIH 285
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Boehringer Ingelheim
Medtronic
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.